TERN (Terns Corp) רווח למניה בארבעת הרבעונים האחרונים

Terns Pharmaceuticals (TERN) is investing in R&D for obesity treatments, anticipating explosive profits following patenting. The annual EPS growth rate over the last 12 months illustrates this trajectory, with the metric holding at 8.60. This positive outlook is further bolstered by sustainable laboratory standards and successful tests of an oral drug, creating strong momentum for the share price as the market awaits Phase 3 results.
TERN (Terns Pharmaceuticals, Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This indicator measures the percentage change in net earnings per share over the last twelve months relative to the same period last year. By analyzing the annual growth rate of EPS (TTM), an investor assesses capitalization efficiency, which for Terns Pharmaceuticals (TERN) depends directly on the uninterrupted supply of chemical components and the stability of international cooperation within clinical trials.